Eyepoint Pharmaceuticals (EYPT) USD0.01
Sell:$6.45Buy:$6.71
$0.17
(2.53%)
- This stock can be held in a
Stocks and Shares ISA$0.17
(2.53%)$0.17
(2.53%)Company Information
About this company
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Key people
Key facts
- EPICEYPT
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS30233G2093
- Market cap$461.17m
- Employees165
- Shares in issue68.73m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.